Characterization of Treatments and Disease Course for Women with Breast Cancer Brain Metastases: 5-Year Retrospective Single Institution Experience

References

• Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(8):1194–1220.31161190
   PubMed Web of Science ®Google Scholar
• Niwińska A, Murawska M, Pogoda K. Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Ann Oncol. 2010;21(5):942–948. doi:10.1093/annonc/mdp40719840953
   PubMed Web of Science ®Google Scholar
• Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004;22(14):2865–2872. doi:10.1200/JCO.2004.12.14915254054
   PubMed Web of Science ®Google Scholar
• Witzel I, Oliveira-Ferrer L, Pantel K, Müller V, Wikman H. Breast cancer brain metastases: biology and new clinical perspectives. Breast Cancer Res. 2016;18(1):8. doi:10.1186/s13058-015-0665-126781299
   PubMed Web of Science ®Google Scholar
• Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer. 2006;107(4):696–704. doi:10.1002/cncr.2204116826579
   PubMed Web of Science ®Google Scholar
• Brosnan EM, Anders CK. Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies. Ann Transl Med. 2018;6(9):163. doi:10.21037/atm.2018.04.3529911111
   PubMed Web of Science ®Google Scholar
• Bendell JC, Domchek SM, Burstein HJ, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer. 2003;97(12):2972–2977. doi:10.1002/cncr.1143612784331
   PubMed Web of Science ®Google Scholar
• Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer. 2008;113(10):2638–2645. doi:10.1002/cncr.2393018833576
   PubMed Web of Science ®Google Scholar
• Kim YJ, Kim JS, Kim IA. Molecular subtype predicts incidence and prognosis of brain metastasis from breast cancer in SEER database. J Cancer Res Clin Oncol. 2018;144(9):1803–1816. doi:10.1007/s00432-018-2697-229971531
   PubMed Web of Science ®Google Scholar
• Sperduto PW, Mesko S, Li J, et al. Beyond an updated graded prognostic assessment (Breast GPA): a prognostic index and trends in treatment and survival in breast cancer brain metastases from 1985 to today [published correction appears in Int J Radiat Oncol Biol Phys. 2021 Jan 1;109(1):303]. Int J Radiat Oncol Biol Phys. 2020;107(2):334–343. doi:10.1016/j.ijrobp.2020.01.05132084525
   PubMed Web of Science ®Google Scholar
• Sperduto PW, Kased N, Roberge D, et al. The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer. J Neurooncol. 2013;112(3):467–472. doi:10.1007/s11060-013-1083-923462853
   PubMed Web of Science ®Google Scholar
• Jin J, Gao Y, Zhang J, et al. Incidence, pattern and prognosis of brain metastases in patients with metastatic triple negative breast cancer. BMC Cancer. 2018;18(1):446. doi:10.1186/s12885-018-4371-029673325
   PubMed Web of Science ®Google Scholar
• Lee S, Ahn HK, Park YH, et al. Leptomeningeal metastases from breast cancer: intrinsic subtypes may affect unique clinical manifestations. Breast Cancer Res Treat. 2011;129(3):809–817. doi:10.1007/s10549-011-1682-021785952
   PubMed Web of Science ®Google Scholar
• Lee YC, Hsieh CC, Chuang JP, Li CY. The necessity of intrathecal chemotherapy for the treatment of breast cancer patients with leptomeningeal metastasis: a systematic review and pooled analysis. Curr Probl Cancer. 2017;41(5):355–370. doi:10.1016/j.currproblcancer.2017.07.00128779849
   PubMed Web of Science ®Google Scholar
• Gounder MM, Spriggs DR. Inclusion of patients with brain metastases in Phase I trials: an unmet need. Clin Cancer Res. 2011;17(12):3855–3857. doi:10.1158/1078-0432.CCR-11-075921527561
   PubMed Web of Science ®Google Scholar
• Rosner D, Nemoto T, Lane WW. Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer. 1986;58(4):832–839. doi:10.1002/1097-0142(19860815)58:4<832::aid-cncr2820580404>3.0.co;2-w3755076
   PubMed Web of Science ®Google Scholar
• Rivera E, Meyers C, Groves M, et al. Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer. 2006;107(6):1348–1354. doi:10.1002/cncr.2212716909414
   PubMed Web of Science ®Google Scholar
• Kim JS, Kim IA. Evolving treatment strategies of brain metastases from breast cancer: current status and future direction. Ther Adv Med Oncol. 2020;12:1758835920936117. doi:10.1177/175883592093611732636942
   PubMed Web of Science ®Google Scholar
• Salvati M, Cervoni L, Innocenzi G, Bardella L. Prolonged stabilization of multiple and single brain metastases from breast cancer with tamoxifen. Report of three cases. Tumori J. 1993;79(5):359–362. doi:10.1177/030089169307900516
   PubMed Web of Science ®Google Scholar
• Wang Q, Sun B, Liu C, et al. Brain metastases from breast cancer may respond to endocrine therapy: report of two cases. Onco Targets Ther. 2019;12:1389–1393. doi:10.2147/OTT.S18814330863105
   PubMed Web of Science ®Google Scholar
• Tolaney SM, Sahebjam S, Le Rhun E, et al. A phase II study of abemaciclib in patients with brain metastases secondary to hormone receptor-positive breast cancer. Clin Cancer Res. 2020;26(20):5310–5319. doi:10.1158/1078-0432.CCR-20-176432694159
   PubMed Web of Science ®Google Scholar
• Phase II multicenter single-arm study of BKM120 plus capecitabine for breast cancer patients with brain metastases. Available from: https://clinicaltrials.gov/ct2/show/NCT02000882. Accessed July 26, 2021.
   Google Scholar
• Swain SM, Baselga J, Miles D, et al. Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA. Ann Oncol. 2014;25(6):1116–1121. doi:10.1093/annonc/mdu13324685829
   PubMed Web of Science ®Google Scholar
• Montemurro F, Delaloge S, Barrios CH, et al. Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial. Ann Oncol. 2020;31(10):1350–1358. doi:10.1016/j.annonc.2020.06.02032634611
   PubMed Web of Science ®Google Scholar
• Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382(7):610–621. doi:10.1056/NEJMoa191451031825192
   PubMed Web of Science ®Google Scholar
• A phase 3, multicenter, randomized, open-label, active-controlled study of trastuzumab deruxtecan (DS-8201a), an anti-HER2-antibody drug conjugate, versus treatment of investigator’s choice for HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with T-DM1. Available from: https://clinicaltrials.gov/ct2/show/NCT03523585. Accessed July 26, 2021.
   Google Scholar
• Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382(7):597–609. doi:10.1056/NEJMoa191460931825569
   PubMed Web of Science ®Google Scholar
• Bachelot T, Romieu G, Campone M, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group Phase 2 study. Lancet Oncol. 2013;14(1):64–71. doi:10.1016/S1470-2045(12)70432-123122784
   PubMed Web of Science ®Google Scholar
• Freedman RA, Gelman RS, Anders CK, et al. TBCRC 022: a phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases. J Clin Oncol. 2019;37(13):1081–1089. doi:10.1200/JCO.18.0151130860945
   PubMed Web of Science ®Google Scholar
• Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322(8):494–500. doi:10.1056/NEJM1990022232208022405271
   PubMed Web of Science ®Google Scholar
• Jeene PM, de Vries KC, van Nes JGH, et al. Survival after whole brain radiotherapy for brain metastases from lung cancer and breast cancer is poor in 6325 Dutch patients treated between 2000 and 2014. Acta Oncol. 2018;57(5):637–643. doi:10.1080/0284186X.2017.141853429276848
   PubMed Web of Science ®Google Scholar
• Halasz LM, Uno H, Hughes M, et al. Comparative effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for patients with brain metastases from breast or non-small cell lung cancer. Cancer. 2016;122(13):2091–2100. doi:10.1002/cncr.3000927088755
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Serizawa T, Shuto T, et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol. 2014;15(4):387–395. doi:10.1016/S1470-2045(14)70061-024621620
   PubMed Web of Science ®Google Scholar